A blood serum diagnostic test that is to be made available for patients with Alzheimer’s disease has demonstrated high sensitivity and specificity, it has been revealed.
Power3 Medical Products, a proteomics company specializing in the development and commercialization of diagnostic examinations for the early detection of neurodegenerative diseases and breast cancer, has provided an interim status report for its international validation study of the company’s NuroPro blood serum biomarker test.
Currently, the company is undergoing the testing of 300 patients in order to obtain clinical validation for its test, Medical News Today notes.
Director of the firm’s laboratory Dr Essam Sheta said: "This study confirms Power3’s panel of neurodegenerative biomarkers’ ability to diagnose Alzheimer’s disease with superior sensitivity and specificity with results in the 95 percent range."
In addition, Dr Marwan Sabbagh, the director of Clinical Research at the Cleo Roberts Center of Clinical Research, said that globally clinicians looked forward to adding a tool to diagnose and treat Alzheimer’s earlier and therefore give the best care to patients.
This month, a study published in the August 5th issue of Neurology revealed that a seafood diet may prevent memory loss.
